Alzheimer’s Drugs Clinical Trials and News: A Round-up


Whereas information about anti-amyloid medication like Leqembi and donanemab stole the highlight, drug firms with different remedy approaches made their main bulletins.

The monoclonal antibody medication focusing on the mind’s amyloid plaques dominated the information cycle in 2023. Eisai and Biogen’s Leqembi was accepted by the FDA — first by means of the accelerated approval pathway in January and full approval in July —  for treating delicate cognitive impairment and early Alzheimer’s illness. The drug cleared out pathological beta-amyloid plaques within the mind and slowed cognitive decline a bit. Nevertheless, some clinicians aren’t certain whether or not these modifications are noticeable and whether or not they outweigh a number of the dangers related to the drug.

Eli Lilly’s anti-amyloid drug donanemab additionally made an enormous hubbub. Researchers introduced constructive outcomes from Part 2 and Part 3 scientific trials and submitted knowledge to the FDA, which can resolve whether or not to approve the drug later this yr. 

Nevertheless, many different biotechnology and drug firms have additionally made vital bulletins and progressed in growing different kinds of medication to deal with Alzheimer’s.  Listed here are the updates you may need missed.

Extra medication focusing on amyloid

Firms are growing medication within the type of vaccines, capsules, and antibodies which goal beta-amyloid plaques not directly to deal with delicate cognitive impairment and early-stage Alzheimer’s.


A number of firms are growing vaccines that practice the physique’s immune system to battle off beta-amyloid. AC Immune and Vaxxinity have each obtained FDA fast-track designations for his or her vaccines, which can velocity up the assessment of those medication sooner or later.

Small-molecule medication 

Different firms are growing small-molecule medication, capsules or capsules that don’t require intravenous infusion.

  • Alzheon’s ALZ-801: This drug prevents wholesome types of beta-amyloid from turning poisonous and sticking collectively. Its Part 2 examine means that the drug might sluggish the development of Alzheimer’s and, importantly, is protected for individuals carrying the APOE4 Alzheimer’s gene who’re in any other case liable to mind bleeds from anti-amyloid medication like Leqembi. The drug is presently being examined in Part 3 trials. 
  • Cognition Therapeutics’ Elayta: The corporate introduced that they’re recruiting contributors for a Part 2 trial of its Elayta, which prevents beta-amyloid proteins from sticking to mind cells.

Extra antibodies

True Binding developed an antibody-based drug that forestalls beta-amyloid from aggregating by focusing on the protein that enables beta-amyloid plaques to stay collectively. It introduced some Part 2 knowledge suggesting that the drug might sluggish cognitive decline.

Teeing up tau as the subsequent goal

A number of firms goal tau protein tangles within the mind — that are thought-about main drivers of cognitive decline.

Most of those medication are geared toward treating delicate cognitive impairment and the early levels of Alzheimer’s.

  • Johnson & Johnson/AC Immune’s ACI-35.030: This vaccine teaches the physique’s immune system tips on how to battle off tau proteins. The corporate introduced that they may check their drug in a Part 2 trial of 500 contributors who’ve tau and are liable to growing Alzheimer’s.
  • Axon Neurosciences AADvac1: The corporate introduced Part 2 knowledge for its AADvac1 tau vaccine. The vaccine might have slowed cognitive decline in a single subset of sufferers.
  • Biogen’s BIIB080: This drug is without doubt one of the first gene therapies in improvement for Alzheimer’s illness. It really works by “silencing” the tau gene in order that tau tangles don’t kind. Biogen shall be shifting this drug to Part 2 trials.
  • Bristol Meyer Squibb/Prothena’s PRX005: The drug is a monoclonal antibody designed to focus on tau proteins within the mind. It attaches to tau and tells the immune system to destroy the pathological protein. Knowledge introduced in 2023 by Prothena means that the drug is protected.
  • Oligomerix’s OLX-07010: Oligomerix started testing its small-molecule drug OLX-07010, which prevents tau proteins from sticking collectively, in Part 1 trials this yr.

Medication focusing on irritation and cell dying

Many different medication, in a method or one other, goal the mind to switch the immune system, scale back irritation and shield mind cells from dying.

  • Anavex Life Sciences’ blarcamesine: The corporate introduced knowledge from the Part 2b/Part 3 trial of its neuroprotective drug, displaying it might sluggish cognitive decline by over 48 weeks
  • BioVie Pharma’s NE3107: The corporate introduced its drug failed the Part 3 trial of its immune-modulating drug. The corporate wrote in its press launch that the failure occurred partly as a result of 15 of its 39 scientific trial websites didn’t comply with examine protocol and violated good scientific apply.
  • Cassava Sciences’ simufilam: The corporate introduced extra knowledge from its Part 2 trial of simufilam. This was overshadowed by allegations of misconduct and an investigation of one of many lead researchers behind the drug. A Part 3 trial is ongoing.
  • COYA Therapeutics’ COYA 301: The corporate’s injectable drug, which stimulates T-regulatory immune cells, was discovered protected and doubtlessly promising in a cohort of 8 sufferers in varied levels of Alzheimer’s illness.
  • Longeveron’s lomcel-B: In Part 2 trials of the drug, made out of bone marrow stem cells, researchers discovered it was protected and will sluggish cognitive decline.
  • Synaptogenix’s bryostatin-1: The corporate introduced Part 2 knowledge of the corporate’s immune-modulating drug in sufferers with average and extreme Alzheimer’s. The information suggests the drug may solely sluggish decline in extreme sufferers.
  • T3D Therapeutics’ TD-359: The drug acts like “insulin for the mind” and helps stop mind cells from ravenous. Its Part 2 trial in sufferers with delicate Alzheimer’s illness was not constructive. The researchers discovered one subgroup, outlined after the trial, did seem to learn.
  • Cognito Therapeutics: The corporate developed a wearable machine that makes use of particular sounds and wavelengths of sunshine to stimulate a particular type of mind exercise referred to as gamma oscillations. Its Part 2 trial means that the machine might sluggish cognitive decline and forestall mind shrinkage in sufferers with delicate to average Alzheimer’s.

If you happen to discover our articles and interviews useful, please think about changing into a supporting member of our group. Pissed off by the dearth of an editorially impartial supply of knowledge on mind well being and Alzheimer’s illness, we determined to create Being Affected person. We’re a crew of devoted journalists overlaying the newest analysis on Alzheimer’s, bringing you entry to the specialists and elevating the affected person perspective on what it’s prefer to reside with dementia.

Please assist help our mission.